Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term ovarian cancer. Found 45 abstracts

no pagination
Diaz Osterman CJ, Ozmadenci D, Kleinschmidt EG, Taylor KN, Barrie AM, Jiang S, Bean LM, Sulzmaier FJ, Jean C, Tancioni I, Anderson K, Uryu S, Cordasco EA, Li J, Chen XL, Fu G, Ojalill M, Rappu P, Heino J, Mark AM, Xu G, Fisch KM, Kolev VN, Weaver DT, Pachter JA, Gyorffy B, McHale MT, Connolly DC, Molinolo A, Stupack DG, Schlaepfer DD. FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy. eLife. 2019 Sep 03;8.   PMCID: PMC6721800
Rodriguez-Garcia A, Sharma P, Poussin M, Boesteanu AC, Minutolo NG, Gitto SB, Omran DK, Robinson MK, Adams GP, Simpkins F, Powell DJ. CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies. Molecular therapy : the journal of the American Society of Gene Therapy. 2019 Dec 06;.
Sawyer TW, Koevary JW, Rice FP, Howard CC, Austin OJ, Connolly DC, Cai KQ, Barton JK. Quantification of multiphoton and fluorescence images of reproductive tissues from a mouse ovarian cancer model shows promise for early disease detection. Journal of biomedical optics. 2019 Sep;24(9):1-16.   PMCID: PMC6768507
Ackroyd SA, Brown J, Houck K, Chu C, Mantia-Smaldone G, Rubin S, Hernandez E. A preoperative risk score to predict red blood cell transfusion in patients undergoing hysterectomy for ovarian cancer. American journal of obstetrics and gynecology. 2018 Sep 18;219(6):598 e1-598 e10.
Jung S, Allen N, Arslan AA, Baglietto L, Barricarte A, Brinton LA, Egleston BL, Falk RT, Fortner RT, Helzlsouer KJ, Gao Y, Idahl A, Kaaks R, Krogh V, Merritt MA, Lundin E, Onland-Moret NC, Rinaldi S, Schock H, Shu XO, Sluss PM, Staats PN, Sacerdote C, Travis RC, Tjonneland A, Trichopoulou A, Tworoger SS, Visvanathan K, Weiderpass E, Zeleniuch-Jacquotte A, Dorgan JF. Anti-Mullerian hormone and risk of ovarian cancer in nine cohorts. International journal of cancer. 2018 Jan 15;142(2):262-70.   PMCID: PMC5749630
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Vergote I, Ponte JF, Birrer MJ. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol. 2018 Jan;14(2):123-36.   PMCID: Review
Prudnikova TY, Chernoff J. The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin. Small GTPases. 2017 Oct 02;8(4):193-8.   PMCID: PMC5680705
Prudnikova TY, Chernoff J. The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin. Small GTPases. 2016 Jul 18;:1-6.
Howard JH, Frolov A, Tzeng CW, Stewart A, Midzak A, Majmundar A, Godwin AK, Heslin MJ, Bellacosa A, Arnoletti P. Epigenetic downregulation of the DNA repair gene MED1/MBD4 in colorectal and ovarian cancer. Cancer Biology & Therapy. 2009 Jan;8(1):94-100.   PMCID: PMC2683899
Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, Hensley ML, Spriggs DR, Aghajanian CA. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecologic Oncology. 2008 Aug;110(2):140-5.
Cai KQ, Yang WL, Capo-Chichi CD, Vanderveer L, Wu H, Godwin AK, Xu XX. Prominent expression of metalloproteinases in early stages of ovarian turnorigenesis. Molecular Carcinogenesis. 2007 Feb;46(2):130-43.
Fujiwara K, Armstrong D, Morgan M, Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. International Journal of Gynecological Cancer. 2007 Jan;17(1):1-20.
Hensley H, Quinn BA, Wolf RL, Litwin SL, Mobuchi S, Williams SJ, Williams C, Hamilton TC, Connolly DC. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biology & Therapy. 2007 Nov;6(11):1717-25.
Hess LM, Barakat R, Tian C, Ozols RF, Alberts DS. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 2007 Nov;107(2):260-5.
Posadas EM, Liel MS, Kwitkowski V, Minasian L, Godwin AK, Hussain MM, Espina V, Wood BJ, Steinberg SM, Kohn EC. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer. 2007 Apr;109(7):1323-30.
Bookman MA, McMeekin DS, Fracasso PM. Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: A phase I study of the Gynecologic Oncology Group. Gynecologic Oncology. 2006 Nov;103(2):473-8.
Chen XW, Truong TT, Weaver J, Bove BA, Cattie K, Armstrong BA, Daly MB, Godwin AK. Intronic alterations in BRCA1 and BRCA2: Effect on mRNA splicing fidelity and expression. HUMAN MUTATION. 2006 May;27(5):427-35.
Pan ZZ, Bruening W, Godwin AK. Involvement of RHO GTPases and ERK in synuclein-gamma enhanced cancer cell motility. INTERNATIONAL JOURNAL OF ONCOLOGY. 2006 Nov;29(5):1201-5.
Bookman MA. Standard treatment in advanced ovarian cancer in 2005: the state of the art. International Journal of Gynecological Cancer. 2005 Nov 03;15:212-20.
Bookman MA. Is there still a role for hormonal therapy?. International Journal of Gynecological Cancer. 2005 Nov 03;15:291-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term ovarian cancer

ovarian cancer CARCINOMA chemotherapy PACLITAXEL carboplatin randomized-trial protein kinase paclitaxel EPIDERMAL-GROWTH-FACTOR STAGE-III breast cancer PROGRESSION CARBOPLATIN oncogene GYNECOLOGIC-ONCOLOGY-GROUP gynecologic-oncology-group chromosomal amplification CELL LUNG-CANCER sensitized screen p21 inactivated kinase signal transduction folate receptor-alpha RISK NMD Misiir aberrant transcript RECEPTOR TYROSINE KINASE MICROSATELLITE Tumor Cell Line methylation BREAST-CANCER cetuximab receptor tamoxifen high-dose carboplatin p21-Activated Kinases CETUXIMAB BRCA2 breast-cancer stage-iii BMI body weight Female SYSTEMIC CHEMOTHERAPY Pyrimidines sporadic breast-cancer gene Ovarian Neoplasms stimulation TRIAL immunotherapy PHYSICAL-ACTIVITY CHEMOTHERAPY PROSTATE-CANCER family Pyrazines epithelial ovarian-cancer preclinical BRCA1 CISPLATIN intraperitoneal cisplatin phase-iii trial INTRAVENOUS CISPLATIN Acetophenones INFUSION anti-Mullerian hormone ovarian-cancer topotecan variants of unknown significance CANCER-RISK Human Chromosomes-Pair 11 epidermal growth factor receptor GTPase nonsense MED1 Oncology transfusion OVULATION standard therapy cell motility transgenic mouse model model epidemiology cancer biology protein array primary peritoneal cancer MATRIX METALLOPROTEINASES CARBOPLATIN-BASED CHEMOTHERAPY MUTATIONS KF GX-BG-MM-DC-AM-DS-DS No competing interests declared-VK Former SURFACE EPITHELIAL-CELLS CAR T cell therapy OBESITY basement MRI micro-imaging preneoplastic changes doublets focal adhesion kinase FAK ERK tumorspheres mouse DOUBLETS estrogen replacement therapy POSTMENOPAUSAL WOMEN CISPLATIN-BASED CHEMOTHERAPY TUMOR OVERWEIGHT phase-ii trial mirvetuximab soravtansine antibody-drug conjugate phase II pathology 1st-line treatment MED1 MBD4 Misr2 epithelium Genetics & Heredity PROPHYLACTIC OOPHORECTOMIES nonsense-mediated mRNA decay cell lung-cancer Piperidines mouse model hysterectomy colorectal cancer EXTRACELLULAR-MATRIX growth-factor ovarian function cell-proliferation RHO genetics tamoxifen therapy ISLAND METHYLATOR PHENOTYPE drug effects TERM-FOLLOW-UP GLYCOSYLASE MBD4 HMLH1 multiphoton imaging splicing gefitinib survival TRANSGENIC MICE Misrii platinum chemotherapy hormone therapy PHASE-II TRIAL fluorescence imaging MORTALITY PROMOTER HYPERMETHYLATION TUMORIGENICITY Amhr2
Last updated on Wednesday, February 05, 2020